ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,245.37
-0.48%
Dow Jones
38,798.99
-0.22%
Gold vs US Dollar
2,293.845
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,398.10
0.09%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Roivant Sciences Ltd (ROIV)

  7. Roivant Sciences Ltd (ROIV) News

Roivant Sciences (ROIV)

Roivant Sciences Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ROIV
DateTimeSourceHeadlineSymbolCompany
31/05/202402:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
30/05/202421:46Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ROIVRoivant Sciences Ltd
30/05/202412:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202412:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ROIVRoivant Sciences Ltd
30/05/202412:00GlobeNewswire Inc.Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/05/202402:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202402:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
23/05/202402:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ROIVRoivant Sciences Ltd
16/05/202421:05GlobeNewswire Inc.Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024NASDAQ:ROIVRoivant Sciences Ltd
02/04/202412:00GlobeNewswire Inc.Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 MillionNASDAQ:ROIVRoivant Sciences Ltd
26/03/202422:22PR Newswire (US)Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600NASDAQ:ROIVRoivant Sciences Ltd
13/02/202412:00GlobeNewswire Inc.Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
30/01/202421:05GlobeNewswire Inc.Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024NASDAQ:ROIVRoivant Sciences Ltd
20/12/202321:30GlobeNewswire Inc.Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ DiseaseNASDAQ:ROIVRoivant Sciences Ltd
14/12/202314:00GlobeNewswire Inc.Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel DiseaseNASDAQ:ROIVRoivant Sciences Ltd
28/11/202312:00GlobeNewswire Inc.Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNASDAQ:ROIVRoivant Sciences Ltd
27/11/202313:00GlobeNewswire Inc.Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNASDAQ:ROIVRoivant Sciences Ltd
13/11/202312:00GlobeNewswire Inc.Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
10/11/202313:00GlobeNewswire Inc.Roivant Announces Appointment of Mayukh Sukhatme to Its Board of DirectorsNASDAQ:ROIVRoivant Sciences Ltd
30/10/202321:30GlobeNewswire Inc.Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023NASDAQ:ROIVRoivant Sciences Ltd
23/10/202320:41Dow Jones NewsTrending: Roche to Buy Telavant From Roivant and PfizerNASDAQ:ROIVRoivant Sciences Ltd
23/10/202312:18IH Market NewsMonday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and moreNASDAQ:ROIVRoivant Sciences Ltd
23/10/202309:16Dow Jones NewsRoche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- UpdateNASDAQ:ROIVRoivant Sciences Ltd
23/10/202306:50Dow Jones NewsRoche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion DealNASDAQ:ROIVRoivant Sciences Ltd
23/10/202306:00GlobeNewswire Inc.Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From RoivantNASDAQ:ROIVRoivant Sciences Ltd
13/10/202313:00GlobeNewswire Inc.Covant Therapeutics Appoints Vincent Hennemand as Chief Executive OfficerNASDAQ:ROIVRoivant Sciences Ltd
26/09/202311:00GlobeNewswire Inc.Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD ResultsNASDAQ:ROIVRoivant Sciences Ltd
11/09/202313:00GlobeNewswire Inc.Roivant Announces Completion of Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
17/08/202321:05GlobeNewswire Inc.Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding WarrantsNASDAQ:ROIVRoivant Sciences Ltd
14/08/202312:00GlobeNewswire Inc.Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business UpdateNASDAQ:ROIVRoivant Sciences Ltd
 Showing the most relevant articles for your search:NASDAQ:ROIV

Your Recent History

LSE
GDR
Genedrive
LSE
POS
Plexus
LSE
LLOY
Lloyds Banking
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
SRSP
Sirius Petroleum
LSE
EEE
Empire Metals
LSE
SHED
Urban Logistics Reit
LSE
SOLG
Solgold
LSE
SRT
Srt Marine Systems
LSE
PHE
Powerhouse Energy
LSE
JWNG
Jaywing
LSE
NG.
National Grid
LSE
BARC
Barclays
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved